摘要
目的:探讨喹硫平联合舍曲林治疗慢性精神分裂症患者的疗效与安全性。方法:82例慢性精神分裂症患者随机分为合用组和单用组,各41例。合用组患者给予喹硫平联合舍曲林治疗;单用组患者单纯给予喹硫平治疗,两组患者的疗程均为12周。于患者治疗前和治疗后4、8、12周,采用阳性和阴性症状量表(PANSS)、阴性症状量表(SANS)评定患者的临床疗效;不良反应量表(TESS)评定患者的不良反应。结果:治疗12周后,合用组患者的PANSS总分、阴性症状分,SANS总分及部分分量表分较治疗前显著降低(P<0.01);阴性因子分显著低于单用组(P<0.05)。两组患者不良反应无明显差异。结论:喹硫平联合舍曲林治疗慢性精神分裂症患者的疗效好,且不良反应少。
Objective: To explore efficacy and safety of Quetiapine combined with Sertraline in treatment of chronic schizo-phrenia. Methods:82 patients with chronic schizophrenia were randomly assigned to combined group ( treated with Quetiapine and Sertraline for 12 weeks, n=41) and single group (treated with Sertraline for 12 weeks, n=41). Positive and negative symptom scale ( PANSS) and negative symptom scale ( SANS) were used to assess the efficacy, and treatment emergent symptom scale ( TESS) was used to evaluate adverse reactions before and 4, 8, and 12 weeks after the treatment. Results:12 weeks after the treatment, PANSS total score, negative symptom score, SANS total score and a few scale scores of combined group were decreased more significantly than those before the treatment (P﹤0. 01). The negative factor scores of combined group were significantly lower than those of single group (P﹤0. 05). There were no significantly differences in adverse reactions between the two groups. Conclusions: Quetiapine combined with Sertraline has a better efficacy and less adverse reactions in the treatment of the patients with chronic schizophrenia.
出处
《中国民康医学》
2015年第7期32-34,共3页
Medical Journal of Chinese People’s Health
关键词
喹硫平
舍曲林
慢性精神分裂症
阴性症状
Quetiapine
Sertraline
Chronic schizophrenia
Negative symptoms
